Bide Pharmatech Co

Bide Pharmatech Co P/CF

The P/CF (Price-to-Cash-Flow Ratio) of Bide Pharmatech Co (688073.SS) as of Nov 5, 2026 is 190.19. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was 34.03 — a change of 458.93% (higher).

P/CF

190.19

YoY

458.93%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of Bide Pharmatech Co is 2025 190.19 . P/CF (Price-to-Cash-Flow Ratio) of Bide Pharmatech Co was 2024 34.03 . It decreases by 458.93% higher compared to the previous year.

The Bide Pharmatech Co P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2019
1,802.52 CNY
Jan 1, 2020
1,477.89 CNY
Jan 1, 2021
-83.03 CNY
Jan 1, 2022
180.34 CNY
Jan 1, 2023
-93.87 CNY
Jan 1, 2024
34.03 CNY
Jan 1, 2025
190.19 CNY
The Bide Pharmatech Co P/CF history
YEARP/CFYoY
190.19+458.93%
34.03-136.25%
-93.87-152.05%
180.34-317.21%
-83.03-105.62%
1,477.89-18.01%
1,802.52—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bide Pharmatech Co Stock analysis

What does Bide Pharmatech Co do? Bide Pharmatech Co., Ltd. generates revenue through the research, development, design, production, and sales of pharmaceutical molecular building blocks and scientific reagents. The company's primary products serve drug target discovery, seed compound screening, lead compound discovery, synthesis, and optimization processes. Key markets include Asia Pacific, India, Europe, and the United States, where the firm's offerings are utilized by pharmaceutical companies and research institutions. The business model relies on direct sales of its specialized chemical products to these industry segments. The firm's main focus is on developing molecular building blocks for drug development, with products specifically designed for early-stage pharmaceutical research. These building blocks are essential for creating and refining potential drug candidates. The company's operations span multiple global regions, targeting pharmaceutical manufacturers and academic research organizations that require high-quality chemical compounds for their development pipelines. Bide Pharmatech's revenue streams are derived from the sale of its proprietary molecular building blocks and reagents, which are integral to pharmaceutical R&D processes. The company serves clients in the pharmaceutical sector across Asia Pacific, India, Europe, and the United States, delivering products that support critical stages of drug discovery and development. Bide Pharmatech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bide Pharmatech Co stock

P/CF (Price-to-Cash-Flow Ratio) of Bide Pharmatech Co is 190.19 in 2025.

P/CF (Price-to-Cash-Flow Ratio) of Bide Pharmatech Co changed from 34.03 to 190.19, representing a 458.93% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) Bide Pharmatech Co since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s Bide Pharmatech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Bide Pharmatech Co

All Key Metrics — Bide Pharmatech Co